30:["$","section",null,{"children":[["$","h2",null,{"className":"text-muted-foreground mb-3 text-sm font-semibold tracking-wide uppercase","children":"Key Coverage Criteria"}],["$","div",null,{"className":"shadow-border rounded-xl px-4 py-3","children":["$","ul",null,{"className":"space-y-2","children":[["$","li","0",{"className":"text-sm leading-relaxed","children":"ESA therapy is covered to treat clinically significant anemia by elevating or maintaining red blood cell levels (as demonstrated by Hgb/Hct) to decrease anemia and reduce the need for transfusions."}],["$","li","1",{"className":"text-sm leading-relaxed","children":"End stage renal disease (ESRD) patients on dialysis with anemia (Hgb < 10.0 g/dL or Hct < 30%) are eligible for ESA therapy."}],["$","li","2",{"className":"text-sm leading-relaxed","children":"Chronic kidney disease (not on dialysis) patients with anemia (Hgb < 10.0 g/dL or Hct < 30%) and evidence of marked renal dysfunction (serum creatinine >= 3 mg/dL OR creatinine clearance < 60 mL/min OR GFR < 60 mL/min/1.73 m2) are eligible for ESA therapy."}],["$","li","3",{"className":"text-sm leading-relaxed","children":"Patients with non-myeloid malignancies who have anemia due to concomitant myelosuppressive chemotherapy are eligible for ESA therapy when the hemoglobin immediately prior to initiation or maintenance is < 10.0 g/dL (Hct < 30%)."}],["$","li","4",{"className":"text-sm leading-relaxed","children":"Patients with anemia due to AZT and/or other nucleoside reverse transcriptase inhibitors (NRTIs) for HIV/AIDS with Hgb < 10.0 g/dL or Hct < 30% at initiation are eligible for ESA therapy."}],["$","li","5",{"className":"text-sm leading-relaxed","children":"Selected patients with myelodysplastic syndromes (MDS) with < 10% blasts, pretreatment erythropoietin level ≤ 500 (units as per lab), and anemia (Hgb < 10.0 g/dL or Hct < 30%) are eligible for ESA therapy."}]]}]}]]}]

C14.8, Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx

Prior Authorization

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

`C14.8`, Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx